{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:48:37Z","timestamp":1790135317175,"version":"4.0.1"},"reference-count":179,"publisher":"Elsevier","isbn-type":[{"value":"9780128211670","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.acc.2020.01.001","type":"book-chapter","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T08:23:58Z","timestamp":1581668638000},"page":"13-71","source":"Crossref","is-referenced-by-count":15,"title":["Liquid biopsy in ovarian cancer"],"prefix":"10.1016","member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2020.01.001_bb0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ijgc-00009577-200505001-00008","article-title":"Future options for first-line therapy of advanced ovarian cancer","volume":"15","author":"du Bois","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network. TCGAR","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2020.01.001_bb0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2020.01.001_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0030","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2020.01.001_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/bs.acc.2020.01.001_bb0055","series-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics","first-page":"1111","article-title":"Circulating tumor cells and circulating tumor DNA","author":"Lianidou","year":"2017"},{"key":"10.1016\/bs.acc.2020.01.001_bb0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","article-title":"Early detection of ovarian cancer","volume":"32","author":"Elias","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/bs.acc.2020.01.001_bb0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2018.10.003","article-title":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","volume":"205","author":"Giannopoulou","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13277-015-4299-9","article-title":"Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer","volume":"37","author":"Gasparri","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0080","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ygyno.2014.03.016","article-title":"Circulating and disseminated tumor cells in ovarian cancer: a systematic review","volume":"133","author":"Romero-Laorden","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0090","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejso.2016.05.010","article-title":"Current and future role of circulating tumor cells in patients with epithelial ovarian cancer","volume":"42","author":"Van Berckelaer","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","article-title":"Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer","volume":"145","author":"Lee","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.18632\/oncotarget.22549","article-title":"Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells","volume":"9","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13048-015-0168-9","article-title":"Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis","volume":"8","author":"Cui","year":"2015","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/IGC.0000000000000459","article-title":"The predictive value of circulating tumor cells in ovarian cancer: a meta analysis","volume":"27","author":"Zeng","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0115","article-title":"Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0120","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0125","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.18632\/oncotarget.23943","article-title":"Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0130","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0135","doi-asserted-by":"crossref","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0140","doi-asserted-by":"crossref","first-page":"24303","DOI":"10.18632\/oncotarget.13286","article-title":"ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post therapeutic outcome of ovarian cancer","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0145","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer\u2014establishment of a multi-marker gene panel","volume":"10","author":"Blassl","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0150","first-page":"973","article-title":"Molecular characterization of circulating tumor cells in ovarian cancer","volume":"6","author":"Kolostova","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2015.03.002","article-title":"Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)","volume":"137","author":"Pearl","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2014.06.013","article-title":"Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer","volume":"134","author":"Pearl","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2013.08.006","article-title":"Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients","volume":"131","author":"Liu","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance\u2014a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0185","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","article-title":"Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer","volume":"112","author":"Fan","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2003.08.004","article-title":"Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer","volume":"91","author":"Judson","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/cncr.10250","article-title":"Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis","volume":"94","author":"Marth","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0210","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1002\/cam4.2218","article-title":"The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness","volume":"8","author":"Dong","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0215","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/1471-2407-10-666","article-title":"Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients","volume":"10","author":"Obermayr","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2018.02.020","article-title":"Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients\u2014a study of the OVCAD consortium","volume":"149","author":"Gostner","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0225","first-page":"1203","article-title":"Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers","volume":"7","author":"Kolostova","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2018.5","article-title":"Potential clinical applications of circulating cell-free DNA in ovarian cancer patients","volume":"20","author":"Barbosa","year":"2018","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0245","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ctrv.2013.10.003","article-title":"Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities","volume":"40","author":"Esposito","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1593\/neo.131900","article-title":"Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA","volume":"16","author":"Martignetti","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/bs.acc.2020.01.001_bb0255","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0260","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.acc.2020.01.001_bb0265","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing","volume":"35","author":"Slavin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1016\/bs.acc.2020.01.001_bb0275","doi-asserted-by":"crossref","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0280","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","article-title":"Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma","volume":"16","author":"Arend","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0285","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mgg3.414","article-title":"Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer","volume":"6","author":"Du","year":"2018","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0290","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5468\/ogs.2018.61.3.328","article-title":"Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer","volume":"61","author":"Park","year":"2018","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/bs.acc.2020.01.001_bb0295","doi-asserted-by":"crossref","first-page":"eaan2415","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0300","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","article-title":"Detection of BRCA1\/2 mutations in circulating tumor DNA from patients with ovarian cancer","volume":"8","author":"Ratajska","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0305","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0310","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0325","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0330","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2020.01.001_bb0335","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdq584","article-title":"Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers","volume":"22","author":"Dobrzycka","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0345","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","article-title":"Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer","volume":"193","author":"Swisher","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0350","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/ijgc-00009577-200405000-00006","article-title":"Detection of p53 mutations in the plasma DNA of patients with ovarian cancer","volume":"14","author":"Otsuka","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0355","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2018.05.026","article-title":"ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer","volume":"150","author":"Giannopoulou","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0365","doi-asserted-by":"crossref","first-page":"21429","DOI":"10.18632\/oncotarget.15249","article-title":"RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell free tissues and paired circulating tumor DNA","volume":"8","author":"Giannopoulou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0370","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.7314\/APJCP.2015.16.7.3003","article-title":"Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer","volume":"16","author":"Wang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7754\/Clin.Lab.2013.130446","article-title":"Detection of circulating methylated opioid binding protein\/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma","volume":"60","author":"Zhou","year":"2014","journal-title":"Clin. Lab."},{"key":"10.1016\/bs.acc.2020.01.001_bb0380","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.7314\/APJCP.2014.15.3.1171","article-title":"Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer","volume":"15","author":"Wu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","article-title":"A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA","volume":"130","author":"Zhang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0390","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/147323001204000231","article-title":"Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer","volume":"40","author":"Dong","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0395","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2011.08.029","article-title":"Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer","volume":"123","author":"Bondurant","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2010.09.019","article-title":"Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors","volume":"120","author":"Liggett","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0405","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2353\/jmoldx.2009.080072","article-title":"Differential methylation profile of ovarian cancer in tissues and plasma","volume":"11","author":"Melnikov","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.acc.2020.01.001_bb0410","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","article-title":"Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients","volume":"64","author":"Ibanez de Caceres","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0415","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/1078-0432.CCR-03-0732","article-title":"The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients","volume":"10","author":"Gifford","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0420","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0425","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12916-016-0667-6","article-title":"Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening","volume":"14","author":"Cohen","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0430","doi-asserted-by":"crossref","first-page":"29831","DOI":"10.1038\/srep29831","article-title":"Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers","volume":"6","author":"Harris","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2020.01.001_bb0435","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1471-2407-12-325","article-title":"LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival","volume":"12","author":"Kuhlmann","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0440","article-title":"Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: a retrospective cohort trial","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0445","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.3892\/ol.2015.3771","article-title":"Quantitative analysis of cell-free DNA in ovarian cancer","volume":"10","author":"Shao","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/bs.acc.2020.01.001_bb0450","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.ejca.2014.06.022","article-title":"Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab","volume":"50","author":"Steffensen","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0455","first-page":"3467","article-title":"Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer","volume":"32","author":"No","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2020.01.001_bb0460","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.25602","article-title":"Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients","volume":"128","author":"Wimberger","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.24997","article-title":"Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker","volume":"116","author":"Kamat","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0470","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PDM.0b013e3181359e1f","article-title":"Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer","volume":"17","author":"Capizzi","year":"2008","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0475","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1196\/annals.1368.031","article-title":"Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR","volume":"1075","author":"Kamat","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.acc.2020.01.001_bb0480","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbiotec.2019.04.015","article-title":"Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer","volume":"298","author":"Keseru","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0485","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13048-018-0459-z","article-title":"Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients","volume":"11","author":"Kalavska","year":"2018","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0490","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11010-013-1863-8","article-title":"A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer","volume":"386","author":"Choudhuri","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0495","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/AOG.0b013e3181867bc0","article-title":"Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors","volume":"112","author":"Zachariah","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0500","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4161\/cbt.5.10.3240","article-title":"Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma","volume":"5","author":"Kamat","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/bs.acc.2020.01.001_bb0505","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/19401736.2012.696625","article-title":"Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges","volume":"23","author":"Yu","year":"2012","journal-title":"Mitochondrial DNA"},{"key":"10.1016\/bs.acc.2020.01.001_bb0510","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.gore.2017.06.010","article-title":"BRCA1 reversion mutation acquired after treatment identified by liquid biopsy","volume":"21","author":"Mayor","year":"2017","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/bs.acc.2020.01.001_bb0520","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12916-016-0741-0","article-title":"Genomic profiling for copy number changes in plasma of ovarian cancer patients\u2014a new era for cancer diagnostics?","volume":"14","author":"Kulasingam","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0525","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0530","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2007.12.017","article-title":"DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment","volume":"109","author":"Barton","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygeno.2015.09.001","article-title":"DNA methylation changes in epithelial ovarian cancer histotypes","volume":"106","author":"Earp","year":"2015","journal-title":"Genomics"},{"key":"10.1016\/bs.acc.2020.01.001_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008274","article-title":"An epigenetic signature in peripheral blood predicts active ovarian cancer","volume":"4","author":"Teschendorff","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0545","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdt370","article-title":"Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients","volume":"24","author":"Flanagan","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0550","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-16-1754","article-title":"Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients","volume":"23","author":"Flanagan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0555","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/epi.14.20","article-title":"DNA methylation markers for early detection of women's cancer: promise and challenges","volume":"6","author":"Wittenberger","year":"2014","journal-title":"Epigenomics"},{"key":"10.1016\/bs.acc.2020.01.001_bb0560","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-018-0035-x","article-title":"Clinical utility of circulating non-coding RNAs\u2014an update","volume":"15","author":"Anfossi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0565","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1098\/rstb.2016.0486","article-title":"MicroRNAs and miRceptors: a new mechanism of action for intercellular communication","volume":"373","author":"Fabbri","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/bs.acc.2020.01.001_bb0570","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0575","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer","volume":"126","author":"Kalluri","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2020.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1373\/clinchem.2017.283531","article-title":"RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients","volume":"64","author":"Keup","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0585","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-017-0659-y","article-title":"The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0590","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2016.03.036","article-title":"The biological significance and clinical applications of exosomes in ovarian cancer","volume":"142","author":"Dorayappan","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0595","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/14789450.2016.1165613","article-title":"Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery","volume":"13","author":"Nawaz","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/bs.acc.2020.01.001_bb0600","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","article-title":"Clinical relevance of circulating cell-free microRNAs in ovarian cancer","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0605","first-page":"123","article-title":"Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer","volume":"10","author":"Zheng","year":"2013","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0610","doi-asserted-by":"crossref","DOI":"10.1177\/1724600818766500","article-title":"Identification of circulating microRNAs as diagnostic biomarkers for ovarian cancer: a pooled analysis of individual studies","volume":"33","author":"Zhou","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/bs.acc.2020.01.001_bb0615","doi-asserted-by":"crossref","first-page":"66620","DOI":"10.18632\/oncotarget.18129","article-title":"Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0620","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13048-019-0482-8","article-title":"Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis","volume":"12","author":"Wang","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0625","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1373\/clinchem.2013.213066","article-title":"Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0630","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.tranon.2019.01.006","article-title":"Circulating miRNA profiling of women at high risk for ovarian cancer","volume":"12","author":"Pandey","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0635","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jbiotec.2019.04.003","article-title":"Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer","volume":"297","author":"Marton","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0640","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13048-018-0477-x","article-title":"Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer","volume":"12","author":"Su","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0645","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/1878-0261.12371","article-title":"Exosomal microRNAs as tumor markers in epithelial ovarian cancer","volume":"12","author":"Pan","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0650","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/s41467-018-06434-4","article-title":"Integrated extracellular microRNA profiling for ovarian cancer screening","volume":"9","author":"Yokoi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2020.01.001_bb0655","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13048-018-0458-0","article-title":"Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types","volume":"11","author":"Kobayashi","year":"2018","journal-title":"J. Ovarian Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0660","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/s12885-018-4974-5","article-title":"Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells","volume":"18","author":"Yoshimura","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0665","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12253-018-0392-x","article-title":"Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian cancer","volume":"24","author":"Ren","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0670","first-page":"33","article-title":"Serum microRNA-21 negatively relates to expression of programmed cell death-4 in patients with epithelial ovarian cancer","volume":"19","author":"Mahmoud","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0675","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.11.005","article-title":"Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer","volume":"148","author":"Shah","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0680","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28932","article-title":"Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer","volume":"6","author":"Elias","year":"2017","journal-title":"Elife"},{"key":"10.1016\/bs.acc.2020.01.001_bb0685","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0690","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2016.12.017","article-title":"Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts","volume":"388","author":"Todeschini","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.acc.2020.01.001_bb0695","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lfs.2016.12.007","article-title":"MiR-376a promotion of proliferation and metastases in ovarian cancer: potential role as a biomarker","volume":"173","author":"Yang","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/bs.acc.2020.01.001_bb0700","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IGC.0000000000000846","article-title":"A pilot study of circulating microRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian cancer","volume":"27","author":"Zhu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0705","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2016.05.049","article-title":"Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis","volume":"83","author":"Gong","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/bs.acc.2020.01.001_bb0710","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-42044-8_1","article-title":"Circulating cell-free miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer","volume":"924","author":"Meng","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153902","article-title":"Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer","volume":"11","author":"Zuberi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0720","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1007\/s13277-016-4993-2","article-title":"The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer","volume":"37","author":"Zuberi","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0725","doi-asserted-by":"crossref","first-page":"16923","DOI":"10.18632\/oncotarget.7850","article-title":"Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer","volume":"7","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0730","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.340","article-title":"Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients","volume":"113","author":"Meng","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0735","doi-asserted-by":"crossref","first-page":"36815","DOI":"10.18632\/oncotarget.5766","article-title":"Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre\/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival","volume":"6","author":"Kapetanakis","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0740","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12094-015-1303-1","article-title":"Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features","volume":"17","author":"Zuberi","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0745","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1007\/s13277-015-3191-y","article-title":"Serum microRNA-145 as a novel biomarker in human ovarian cancer","volume":"36","author":"Liang","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0750","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1007\/s13277-015-3138-3","article-title":"MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer","volume":"36","author":"Gao","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0755","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.canlet.2014.10.010","article-title":"A novel serum microRNA panel to discriminate benign from malignant ovarian disease","volume":"356","author":"Langhe","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.acc.2020.01.001_bb0760","article-title":"MiR-26a promotes ovarian cancer proliferation and tumorigenesis","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0765","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.7314\/APJCP.2014.15.4.1739","article-title":"Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients","volume":"15","author":"Ji","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0770","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.795","article-title":"Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes","volume":"110","author":"Shapira","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0775","article-title":"Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0780","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7314\/APJCP.2013.14.2.1057","article-title":"Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2020.01.001_bb0785","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-12-2726","article-title":"Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer","volume":"19","author":"Suryawanshi","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0300060513487652","article-title":"Serum microRNA-92 expression in patients with ovarian epithelial carcinoma","volume":"41","author":"Guo","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0795","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/0300060513475759","article-title":"Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer","volume":"41","author":"Hong","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0800","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/1471-2407-12-627","article-title":"Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer","volume":"12","author":"Kan","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0805","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2008.08.036","article-title":"The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform","volume":"112","author":"Resnick","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0810","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","article-title":"MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer","volume":"110","author":"Taylor","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0815","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1515\/cclm-2018-1048","article-title":"Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance","volume":"57","author":"Kuhlmann","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2020.01.001_bb0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3098542","article-title":"Evaluation of prognostic and predictive significance of circulating microRNAs in ovarian cancer patients","volume":"2017","author":"Halvorsen","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/bs.acc.2020.01.001_bb0825","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605833","article-title":"Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening","volume":"103","author":"Hausler","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2020.01.001_bb0830","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbrc.2013.10.053","article-title":"MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1","volume":"441","author":"Wu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.acc.2020.01.001_bb0835","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biopha.2013.12.001","article-title":"miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells","volume":"68","author":"Jiang","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/bs.acc.2020.01.001_bb0840","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/01443615.2014.919998","article-title":"Circulating microRNA expression profiles in ovarian cancer","volume":"34","author":"Ayaz","year":"2014","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0845","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejogrb.2018.01.006","article-title":"Serum miR-1181 and miR-4314 associated with ovarian cancer: miRNA microarray data analysis for a pilot study","volume":"222","author":"Ruan","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0850","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tjog.2014.07.005","article-title":"Serum microRNAs in clear cell carcinoma of the ovary","volume":"53","author":"Chao","year":"2014","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0855","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/cas.13210","article-title":"MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer","volume":"108","author":"Fukagawa","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/bs.acc.2020.01.001_bb0860","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-17-3014","article-title":"miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway","volume":"78","author":"Salem","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2020.01.001_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141279","article-title":"Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study","volume":"10","author":"Benson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.01.001_bb0870","doi-asserted-by":"crossref","first-page":"43076","DOI":"10.18632\/oncotarget.9246","article-title":"Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2020.01.001_bb0875","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/2211-5463.12257","article-title":"MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor","volume":"7","author":"Xu","year":"2017","journal-title":"FEBS Open. Bio."},{"key":"10.1016\/bs.acc.2020.01.001_bb0880","first-page":"7","article-title":"Cancer statistics 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.acc.2020.01.001_bb0885","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/bs.acc.2020.01.001_bb0890","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-801401-1.00002-5","article-title":"Ovarian cancer biomarkers: current state and future implications from high-throughput technologies","volume":"66","author":"Leung","year":"2014","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0895","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1373\/clinchem.2012.184614","article-title":"The long journey of cancer biomarkers from the bench to the clinic","volume":"59","author":"Pavlou","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.01.001_bb0900","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility","volume":"21","author":"Ignatiadis","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:39:25Z","timestamp":1758742765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242320300123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211670"],"references-count":179,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2020.01.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}